NEW YORK (GenomeWeb News) – The genomics data analysis developer Bina Technologies said this week that it has added three executives to its management ranks, including Take Ogawa, Sharon Barr, and Tom Kanar.
Ogawa, who will be director of field sales, has held senior commercial positions at Complete Genomics, RainDance Technologies, Roche, and Invitrogen, now a Life Technologies business.
Barr, who has been named VP of engineering, formerly held the same title at the database tech firm Couchbase, and he was director of engineering at Yahoo!
Kanar, who will be company CFO, formerly was CFO at Autonet Mobile and at Coapt Systems.
Bina also has hired Shan Yang to be scientific applications and support manager, Larry Kopjak as director of sales operations, and Hugo Lam as a senior member of its computational biology team.
Horizon Discovery has added Ian Gilham to serve on its board of directors as a non-executive director. Gilham is the non-executive chairman of DNA sequencing products maker Multiplicom and the diagnostics company Biosurfit.
He also is director of Stowhealth, which advises private equity and corporate finance organizations investing in clinical diagnostics and medical devices.
Eurofins MWG Operon has appointed James Corne to be director of marketing.
Corne previously was marketing director for several organizations, including Virginia's Local Energy Alliance Program and at Penn State's Sustainability Office. He also was global systems developer at PepsiCo international and consulted with Verizon on a large-scale marketing and sustainability initiative.
Exact Sciences' shareholders have re-elected three members of its board of directors, including company President and CEO Kevin Conroy, as well as Katherine Napier, and David Thompson.
Napier, who has been a director since 2009, spent over two decades at Procter and Gamble, where she was a GM of the firm's North American pharmaceutical business.
Thompson, who spent 30 years at Abbott Laboratories and served as VP and president of Abbott's Laboratories Diagnostics Division, has been a director at Exact Sciences since 2010.
ARCA Biopharma, a firm developing genetically targeted treatments for cardiovascular diseases, has appointed Ray Woosley to its board of directors. Woosley, president emeritus of the Critical Path Institute, will serve on the compensation, nominating, and corporate governance committees of ARCA's board of directors.
From 2005 to 2011, Woosley served as the president, CEO, and chairman of the C-Path Institute, a non-profit, public-private institute with the US Food and Drug Administration that he founded. Last year, Woosley became president and board chairman of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit organization focused on medication safety research and education.
ARCA also announced that Jean-Francois Formela, a partner at Atlas Ventures, has resigned from its board of directors. He had been a member since 2006.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.